Role of adiponectin system in insulin resistance

Caselli, Chiara

doi:10.1016/j.ymgme.2014.09.003

Cited by 91 publications

(74 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The lipodystrophy caused by caveolae loss in fat cells due to PTRF/cavin-1 loss was already noted (21), and this results in an altered pattern of adipokine production. Adipokines affect other tissues in various ways including skeletal muscle where adiponectin, for example, enhances insulin sensitivity (60). There is also a further potential effect of PTRF/cavin-1 deficiency, namely that owing to its caveolae-independent function in the regulation of ribosomal RNA levels that has been demonstrated in adipocytes, which are terminally differentiated cells that require efficient ribosomal function for adequate cell nutrition (61).…”

Section: Discussionmentioning

confidence: 99%

Muscular dystrophy in PTFR/cavin-1 null mice

Ding¹,

Liu²,

Pilch³

2017

JCI Insight

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Muscular dystrophy in PTFR/cavin-1 null mice

Ding¹,

Liu²,

Pilch³

2017

JCI Insight

View full text Add to dashboard Cite

“…Low levels of circulating adiponectin can increase the risk of metabolic syndrome. 29 An orally active adiponectin receptor agonist, AdipoRon, has been developed and shows some promise in pre-clinical studies. 30 …”

Section: Adiponectin Receptor Agonistsmentioning

confidence: 99%

Drug therapies in type 2 diabetes: an era of personalised medicine

Chowdhury

Grant

2016

Clinical Medicine

View full text Add to dashboard Cite

Optimal management of diabetes involves a multidisciplinary approach. Prioritisation of lifestyle change, blood pressure and lipid control, and regular screening for complications are advocated in most international guidelines. Good glucose control, however, remains an important aim of treatment, although it is increasingly recognised that glucose targets should be individualised, with less stringent targets for older patients with significant comorbidities.In recent years, a number of newer therapies for hyperglycaemia have become available. This review aims to discuss currently available options for patients with type 2 diabetes, and also discusses potential new therapies that may be on the horizon in the future.

show abstract

“…These alterations affect the function of adipose tissue [13][14][15][16] and induce changes in the microenvironment that contribute to the recruitment of inflammatory cell leading to a state of chronic low grade inflammation [17,18].…”

Section: Obesity and Inflammationmentioning

confidence: 99%

Adipokines and their Involvement as a Target of New Drugs

Raimo¹

2015

J Pharmacovigil

View full text Add to dashboard Cite

Globesity is referred to a global epidemic of obesity, affecting millions of individuals. Molecules released by the enlarged adipose tissue, most of which are pro-inflammatory, have been named adipokines. The present review deals with function, molecular targets and the potential clinical relevance of adipokines. Currently, more than 600 adipokines have been identified, many of them, including leptin, visfatin, resistin as well as Retinol Binding Protein4 may serve as informative markers for metabolic and cardiovascular diseases and play important roles in glucose homeostasis, insulin sensitivity as well as metabolic regulation of energy expenditure. Adiponectin on the contrary exerts anti-inflammatory and insulin sensitizing activity. Adiponectin has additional anti-atherogenic effects and low adiponectin serum concentrations are associated with in creased risk for cardiovascular diseases. The understanding of the role of adipokines has provided a wealth of information that has opened great opportunities for new therapeutic advances. Adiponectin may be the most prominent example for the potential use of an adipokine in the treatment of obesity and obesity-associated metabolic diseases. In many studies, administration of recombinant adiponectin results in improved insulin sensitivity, increased insulin secretion and beneficial effects on body weight and hyperglycemia. Up-regulation of adiponectin/adiponectin receptors or enhancing adiponectin receptor function may be an interesting therapeutic strategy for obesity-linked insulin resistance. Moreover, the therapeutic use of combined amylin/leptin agonism (with pramlintide and metreleptin) demonstrated a significant weight-lowering effect in obese subjects. Therefore, adipokines may be clinically relevant either as therapeutic tools or as target in the treatment of obesity related diseases. Journal of PharmacovigilanceJou rn a l o f P harma c o v ig il a nc e

show abstract

Role of adiponectin system in insulin resistance

Cited by 91 publications

References 75 publications

Muscular dystrophy in PTFR/cavin-1 null mice

Muscular dystrophy in PTFR/cavin-1 null mice

Drug therapies in type 2 diabetes: an era of personalised medicine

Adipokines and their Involvement as a Target of New Drugs

Contact Info

Product

Resources

About